Is this new News or am I just slow?
REGISTER
The information on this site is not intended or implied to be a substitute for professional medical advice, diagnosis or treatment. Content within the patient forum is user-generated and has not been reviewed by medical professionals. Other sections of the Melanoma Research Foundation website include information that has been reviewed by medical professionals as appropriate. All medical decisions should be made in consultation with your doctor or other qualified medical professional.

Is this new News or am I just slow?

› Forums › General Melanoma Community › Is this new News or am I just slow?

  • Post
    • June 11, 2011 at 7:39 pm
    LynnLuc
    Participant

      http://www.biooncology.com/research-education/braf/metastatic-melanoma/solid-tumors/index.html

      Oncogenic BRAF expression is associated with poor prognosis in metastatic melanoma and other solid tumors

      The molecular signature of a tumor is likely to influence patient prognosis.

      http://www.biooncology.com/research-education/braf/metastatic-melanoma/solid-tumors/index.html

      Oncogenic BRAF expression is associated with poor prognosis in metastatic melanoma and other solid tumors

      The molecular signature of a tumor is likely to influence patient prognosis. While the mutations that result in metastatic melanoma are heterogeneous and can involve other proteins, overactive RAS-RAF signaling is significantly associated with a poorer prognosis (Figure 3). Specifically, the presence of a BRAF mutation in metastatic melanoma is associated with poorer prognosis from time of first metastasis or time from first resected metastasis. Other mutations, such as NRAS, are also more common in this disease state.28-30

      In addition to melanoma, BRAF mutational status is associated with a poor prognosis in other cancers. The presence of mutated BRAF is a powerful prognostic factor for advanced and recurrent colorectal cancer. BRAFV600E is associated with a worse prognosis in stage II and stage III colon cancer independently of disease stage and therapy. In papillary thyroid cancer, the BRAFV600E mutation is associated with an increased risk of nodal recurrence requiring re-operative surgery.28,31,32

       

      Influence of BRAF or NRAS mutation on overall survival (OS). OS was measured from removal of primary tumor or the respective metastasis to time of death. Kaplan-Meier (KM) curves for OS of metastases stratified for absence (purple line) or presence (blue line) of either a BRAF or an NRAS mutation .29

      Adapted with permission of Medknow Publications and Media PVT Ltd., Houben et al. J Carcinog. 2004;3:6; permission conveyed through Copyright Clearance Center, Inc.

    Viewing 5 reply threads
    • Replies
        • June 11, 2011 at 7:45 pm
        lhaley
        Participant

          Date on graph is 2004 in small print on bottom.

            • June 11, 2011 at 7:56 pm
            LynnLuc
            Participant

              darn even with glasses I can't read that 🙂

              • June 11, 2011 at 7:56 pm
              LynnLuc
              Participant

                darn even with glasses I can't read that 🙂

              • June 11, 2011 at 7:45 pm
              lhaley
              Participant

                Date on graph is 2004 in small print on bottom.

                • June 11, 2011 at 8:06 pm
                MichaelFL
                Participant

                  No, this is not new news.

                  The BRAF gene encodes a protein that plays a key role downstream of KRAS in the cell signaling pathway from the Epidermal Growth Factor Receptor (EGFR) that activates important cell functions, including cell proliferation and survival.

                  As you may already be aware as well, this has led to the development of melanoma therapies that specifically inhibit the mutant BRAF such as PLX4032 (vemurafenib, RG7204 or RO5185426), Also be aware that there is no evidence that patients with KRAS/BRAF mutated tumors are less likely to benefit from standard chemotherapy agents.

                  Michael

                  • June 11, 2011 at 8:06 pm
                  MichaelFL
                  Participant

                    No, this is not new news.

                    The BRAF gene encodes a protein that plays a key role downstream of KRAS in the cell signaling pathway from the Epidermal Growth Factor Receptor (EGFR) that activates important cell functions, including cell proliferation and survival.

                    As you may already be aware as well, this has led to the development of melanoma therapies that specifically inhibit the mutant BRAF such as PLX4032 (vemurafenib, RG7204 or RO5185426), Also be aware that there is no evidence that patients with KRAS/BRAF mutated tumors are less likely to benefit from standard chemotherapy agents.

                    Michael

                    • June 12, 2011 at 12:34 pm
                    Cooper
                    Participant

                      What standard chemo are you talking about Michael?  I don't get your response, it looks like a copy and paste from somewhere..  Yes, an Aussie study shows BRAF pos folks had worst prognosis, but they still had options for therapy the others don't have.  But there is no standard chemo for melanoma.

                        • June 12, 2011 at 5:10 pm
                        MichaelFL
                        Participant

                          I was not referring to just melanoma as there are many BRAF mutations in other cancers as well.

                          Thus,I was stating that  there is no evidence that patients with KRAS/BRAF mutated tumors (in other cancers as well as melanoma) are less likely to benefit from standard chemotherapy agents that are used for those cancers.

                          Sorry you didn;'t get it.

                          • June 12, 2011 at 5:10 pm
                          MichaelFL
                          Participant

                            I was not referring to just melanoma as there are many BRAF mutations in other cancers as well.

                            Thus,I was stating that  there is no evidence that patients with KRAS/BRAF mutated tumors (in other cancers as well as melanoma) are less likely to benefit from standard chemotherapy agents that are used for those cancers.

                            Sorry you didn;'t get it.

                          • June 12, 2011 at 12:34 pm
                          Cooper
                          Participant

                            What standard chemo are you talking about Michael?  I don't get your response, it looks like a copy and paste from somewhere..  Yes, an Aussie study shows BRAF pos folks had worst prognosis, but they still had options for therapy the others don't have.  But there is no standard chemo for melanoma.

                        Viewing 5 reply threads

                        Tagged: 

                        • You must be logged in to reply to this topic.
                        About the MRF Patient Forum

                        The MRF Patient Forum is the oldest and largest online community of people affected by melanoma. It is designed to provide peer support and information to caregivers, patients, family and friends. There is no better place to discuss different parts of your journey with this cancer and find the friends and support resources to make that journey more bearable.

                        The information on the forum is open and accessible to everyone. To add a new topic or to post a reply, you must be a registered user. Please note that you will be able to post both topics and replies anonymously even though you are logged in. All posts must abide by MRF posting policies.